Tau and synuclein kinases have been considered as potential therapeutic targets for synucleinopathies and tauopathies and several compounds have been developed for these kinases and tested in preclinical models (for reviews on these topics, see references Vancraenenbroeck et al., 2011; Kramer et al., 2012; Tell and Hilgeroth, 2013). This evidence concerns the gene MAPT and tauopathy.